Compare · MRNA vs SABS
MRNA vs SABS
Side-by-side comparison of Moderna Inc. (MRNA) and SAB Biotherapeutics Inc. (SABS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and SABS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.72B, about 68.0x SABS ($275.3M).
- Over the past year, MRNA is up 77.4% and SABS is up 82.5% - SABS leads by 5.1 points.
- MRNA has been more active in the news (25 items in the past 4 weeks vs 10 for SABS).
- MRNA has more recent analyst coverage (25 ratings vs 12 for SABS).
- Company
- Moderna Inc.
- SAB Biotherapeutics Inc.
- Price
- $47.18-0.82%
- $3.60+0.14%
- Market cap
- $18.72B
- $275.3M
- 1M return
- +3.20%
- +2.71%
- 1Y return
- +77.44%
- +82.49%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 25
- 10
- Recent ratings
- 25
- 12
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
SAB Biotherapeutics Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.
Latest MRNA
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.86% to 66,350 units (SEC Form 4) (for tax liability)
- President Hoge Stephen converted options into 2,047 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,479,054 units (SEC Form 4) (tax liability)
- Director Afeyan Noubar exercised 9,263 shares at a strike of $19.15 and sold $433,879 worth of shares (9,263 units at $46.84) (SEC Form 4)
- SEC Form 144 filed by Moderna Inc.
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $2,581,462 worth of shares (53,336 units at $48.40) as part of a pre-agreed trading plan (SEC Form 4)
- Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism
- Moderna Recognized by TIME as One of the World's Most Impactful Companies
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
- Moderna Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
Latest SABS
- SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
- Citigroup initiated coverage on SAB BIO with a new price target
- Jefferies initiated coverage on SAB BIO with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.
- SEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.
- SEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.
- SEC Form 10-Q filed by SAB Biotherapeutics Inc.
- SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
- SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
- SAB Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits